PEPGEN INC. Proceeds from Stock Plans
PEPGEN INC. (PEPG) reported Proceeds from Stock Plans of $117.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockPlans · last filed 2026-08-06
- PEPGEN INC. proceeds from stock plans for the quarter ending 2026-06-30 was $110.00K, a 12.24% increase year-over-year.
- PEPGEN INC. proceeds from stock plans for the quarter ending 2026-03-31 was $7.00K.
- PEPGEN INC. proceeds from stock plans for the quarter ending 2025-12-31 was $167.00K, a 30.47% increase year-over-year.
- PEPGEN INC. proceeds from stock plans for the quarter ending 2025-09-30 was $27.00K, a 93.37% decline year-over-year.
- PEPGEN INC. proceeds from stock plans for fiscal 2025 was $292.00K, a 88.24% decline from fiscal 2024.
- PEPGEN INC. proceeds from stock plans for fiscal 2024 was $2.48M, a 881.03% increase from fiscal 2023.
- PEPGEN INC. proceeds from stock plans for fiscal 2023 was $253.00K, a 16.59% increase from fiscal 2022.
- PEPGEN INC. proceeds from stock plans for fiscal 2022 was $217.00K.
| Period end | Proceeds from Stock Plans 3 month | Proceeds from Stock Plans 6 month | Proceeds from Stock Plans 9 month | Proceeds from Stock Plans 12 month |
|---|---|---|---|---|
| 2026-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $117.00K 10-Q · filed 2026-08-06 | $284.00K derived: sum of 3 quarters · filed 2026-08-06 | $311.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $7.00K 10-Q · filed 2026-05-12 | $174.00K derived: sum of 2 quarters · filed 2026-05-12 | $201.00K derived: sum of 3 quarters · filed 2026-05-12 | $299.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $167.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $194.00K derived: sum of 2 quarters · filed 2026-03-04 | $292.00K derived: sum of 3 quarters · filed 2026-08-06 | $292.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | $27.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $125.00K derived: sum of 2 quarters · filed 2026-08-06 | $125.00K 10-Q · filed 2025-11-12 | $253.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $98.00K 10-Q · filed 2026-08-06 | $226.00K derived: sum of 3 quarters · filed 2026-08-06 | $633.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $128.00K derived: sum of 2 quarters · filed 2026-05-12 | $535.00K derived: sum of 3 quarters · filed 2026-05-12 | $2.09M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $535.00K derived: sum of 2 quarters · filed 2026-03-04 | $2.09M derived: sum of 3 quarters · filed 2026-03-04 | $2.48M 10-K · filed 2026-03-04 |
| 2024-09-30 | $407.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.96M derived: sum of 2 quarters · filed 2025-11-12 | $2.35M 10-Q · filed 2025-11-12 | $2.39M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.95M 10-Q · filed 2025-08-07 | $1.99M derived: sum of 3 quarters · filed 2025-08-07 | $1.99M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $395.00K 10-Q · filed 2025-05-08 | $433.00K derived: sum of 2 quarters · filed 2025-05-08 | $433.00K derived: sum of 3 quarters · filed 2025-05-08 | $518.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $38.00K derived: sum of 2 quarters · filed 2025-02-24 | $123.00K derived: sum of 3 quarters · filed 2025-02-24 | $253.00K 10-K · filed 2025-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $85.00K derived: sum of 2 quarters · filed 2024-11-07 | $215.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $215.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $130.00K 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | $217.00K 10-K/A · filed 2024-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |